AbstractTreatment of very old patients with non-Hodgkin's lymphoma remains controversial. Indeed, patients over 80 years old are usually not included in trials. We show here that addition of rituximab to reduced-dose CHOP chemotherapy seems to be a good compromise between toxicity and efficacy, allowing clinicians to treat very elderly patients with a curative intent.
Figures & Tables
Vol. 90 No. 9 (2005): September, 2005 : Comparative Studies
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com